threonine has been researched along with pci 32765 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, B; Fang, B; Gao, W; Gold, KA; Heymach, JV; Hofstetter, WL; Lu, H; Minna, J; Ou, Z; Roth, JA; Swisher, SG; Wang, L; Wang, M; Wu, S; Zhang, L | 1 |
| Berglöf, A; Blomberg, KE; Hamasy, A; Mohammad, DK; Smith, CI; Vihinen, M; Wang, Q; Yu, L | 1 |
| Belmont, LD; Bergeron, P; Bowman, K; Burton, L; Choy, R; Crawford, JJ; Eigenbrot, C; Estevez, A; Franke, Y; Gogol, E; Johnson, AR; Katewa, A; Kohli, PB; Li, H; Lin, M; Mortara, K; Ortwine, DF; Penuel, E; Tam, C; Wu, J; Young, WB; Yu, C | 1 |
| Berglöf, A; Estupiñán, HY; Mohammad, DK; Schaafsma, GCP; Shi, Y; Smith, CIE; Vihinen, M; Wang, Q; Yu, L; Zain, R; Zhou, L | 1 |
4 other study(ies) available for threonine and pci 32765
| Article | Year |
|---|---|
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells.
Topics: Adenine; Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Methionine; Mice; Mutation; Piperidines; Pyrazoles; Pyrimidines; Quinazolines; Threonine | 2014 |
Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amino Acid Substitution; Animals; Biocatalysis; Cell Line; Cysteine; Drug Resistance, Neoplasm; Humans; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Threonine; Transfection | 2017 |
Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Cysteine; Humans; Kinetics; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Threonine | 2016 |
BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Benzamides; Cell Line; Cell Line, Tumor; Chickens; Chlorocebus aethiops; COS Cells; Cysteine; Drug Resistance, Neoplasm; HEK293 Cells; Humans; Mutation; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Threonine | 2021 |